8-K: SS Innovations Provides Update on Audit and Trading Status, Appoints New Directors

SS Innovations is restating past financials due to its previous auditor being barred by the SEC, leading to a temporary move to the Expert Market tier, while also adding two new independent directors.

Summary

• SS Innovations is restating its financial statements for 2022 and 2023, as well as interim statements for several quarters in 2023 and 2024, due to its previous auditor, BF Borgers CPA PC, being barred by the SEC.
• The company has engaged BDO India to re-audit the financial statements.
• As a result of not meeting filing deadlines, SS Innovations' stock has been moved from the OTC Pink Tier to the Expert Market, which has limited liquidity and is not considered reflective of the company's market value.
• The company is working to complete the re-audit and file the necessary amended SEC reports to return to the OTC Pink Tier.
• Two new independent directors, Dr. Frederic H. Moll and Timothy P. Adams, have joined the board.
• The company's operations and growth have not been adversely impacted by the auditor issues.
• SS Innovations is developing surgical robotic technologies, including the SSi Mantra system, which has received Indian regulatory approval and is undergoing regulatory approval in the US and EU.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The restatement of financials and move to the Expert Market are significant negatives, while the appointment of new directors and the progress of the SSi Mantra system are positives. Overall, the negative aspects outweigh the positives, resulting in a lower sentiment score.

Positives

• The company has engaged BDO India to re-audit the financial statements.
• Two new independent directors with significant experience in surgical robotics and healthcare have joined the board.
• The company's operations and growth have not been adversely impacted by the auditor issues.
• The SSi Mantra system has received Indian regulatory approval and is undergoing regulatory approval in the US and EU.

Negatives

• The company is restating its financial statements for 2022 and 2023 and several interim periods.
• The company's stock has been moved to the Expert Market due to late filings.
• The Expert Market has extremely limited liquidity and is not considered reflective of the company's market value.

Risks

• The restatement of financial statements could lead to further scrutiny and potential issues.
• The move to the Expert Market could negatively impact investor confidence and liquidity.
• The company is dependent on receiving regulatory approvals in the US and EU for its SSi Mantra system.
• The company is facing delays in filing its financial reports.

Future Outlook

SS Innovations is working to complete the re-audit and file the necessary amended SEC reports to return to the OTC Pink Tier and continue its efforts to complete an uplisting of its common stock. The company anticipates receiving FDA approval to market and CE Mark approval for the SSi Mantra system in 2025.

Management Comments

• The company is working diligently with BDO to complete the audit and the restated financial statements.
• The unfortunate consequences of the Borgers SEC sanctions in no way have adversely impacted the Company's operations and growth.
• The company is moving with all diligence to complete the reaudit, filing the necessary amended SEC reports and as soon as practicable, becoming current with its SEC reporting requirements.

Industry Context

The surgical robotics industry is competitive, with Intuitive Surgical being a major player. SS Innovations aims to provide more affordable and accessible robotic surgery solutions. The appointment of Dr. Frederic H. Moll, a pioneer in the field, signals a commitment to innovation and growth.

Comparison to Industry Standards

• Intuitive Surgical, founded by new SS Innovations director Dr. Frederic H. Moll, is a global leader in surgical robotics, setting a high benchmark for technology and market presence.
• SS Innovations' SSi Mantra system is competing with established robotic surgery systems, aiming to offer a more cost-effective solution.
• The company's current situation with the restatement of financials and move to the Expert Market is not typical for established players in the industry, highlighting the challenges faced by smaller companies.

Management Changes

Stakeholder Impact

• Shareholders are negatively impacted by the restatement of financials and the move to the Expert Market.
• Employees are not directly impacted by the audit issues.
• Customers may be impacted by delays in regulatory approvals.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• Complete the re-audit of financial statements.
• File the necessary amended SEC reports.
• Return to quotation on the OTC Pink Tier.
• Continue efforts to complete an uplisting of its common stock.
• Obtain FDA approval to market and CE Mark approval for the SSi Mantra system.

Key Dates

Keywords

surgical robotics, financial restatement, audit, SEC, OTC market, Expert Market, BDO India, SSi Mantra, regulatory approval, independent directors